Nuvation Bio Inc. (NUVB)
| Market Cap | 3.07B |
| Revenue (ttm) | 26.75M |
| Net Income (ttm) | -217.48M |
| Shares Out | 342.83M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,762,300 |
| Open | 8.88 |
| Previous Close | 8.94 |
| Day's Range | 8.87 - 9.12 |
| 52-Week Range | 1.54 - 9.75 |
| Beta | 1.59 |
| Analysts | Strong Buy |
| Price Target | 10.63 (+18.64%) |
| Earnings Date | Nov 3, 2025 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and ext... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $10.63, which is an increase of 18.64% from the latest price.
News
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positiv...
Nuvation Bio: A Strong Company Now Fairly Priced
Nuvation Bio (NUVB) is downgraded from Buy to Hold as its stock price now reflects improved Ibtrozi rollout visibility and strong fundamentals. Ibtrozi's commercial launch is robust, with early patien...
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Fou...
Nuvation Bio Inc. (NUVB) Presents at Jefferies London Healthcare Conference 2025 Transcript
Nuvation Bio Inc. ( NUVB) Jefferies London Healthcare Conference 2025 November 19, 2025 10:00 AM EST Company Participants David Hung - Founder, President, CEO & Chairman Philippe Sauvage - CFO & Prin...
Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case
Nuvation Bio is demonstrating strong early commercial success with Ibtrozi, its newly FDA-approved therapy for ROS1-positive non-small cell lung cancer. NUVB reported 204 new patients for Ibtrozi in t...
Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript
Nuvation Bio Inc. ( NUVB) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Robert DeVita David Hung - Founder, President, CEO & Chairman Colleen Sjogren - Chief Commercial Offi...
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the t...
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first pa...
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference ...
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it has enrolled the first ...
3 Of My Favorite Biotech Stocks Under $10
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited ...
Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan's Ministry of H...
Nuvation Bio: A Rare Gem In The Risky Biotech Space
Nuvation Bio is a compelling long-term biotech investment following FDA approval and the strong early launch of IBTROZI (taletrectinib) for ROS1+ NSCLC. IBTROZI's superior efficacy, rapid uptake, and ...
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new and updated results fr...
Top 2 Health Care Stocks That May Plunge This Month
As of Sept. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Nuvation Bio: What To Expect From IBTROZI Launch?
Nuvation Bio is a Buy after FDA approval of Ibtrozi, a highly selective ROS1+ NSCLC treatment with strong clinical results and brain metastasis efficacy. Ibtrozi demonstrated superior response rates a...
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quart...
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be pres...
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference ...
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZ...
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
LOUISVILLE, Ky., June 16, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc. for IBTROZI™ (taletrectin...
US FDA approves Nuvation Bio's lung cancer therapy
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Dru...